Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Catalyst Pharmaceuticals Inc
CN2Current price
20.17 EUR
-1.1 EUR (-5.17%)
Last closed
21.69 USD
Company
www.catalystpharma.com
ISIN
US14888U1016
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
2 854 202 880 USD
Yield for 12 month
+49.17 %
1Y
3Y
5Y
10Y
15Y
CN2
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida. Address: 355 Alhambra Circle, Coral Gables, FL, United States, 33134
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
31 USDP/E ratio
20.2797Dividend Yield
–Current Year
+398 204 000 USD
Last Year
+214 203 000 USD
Current Quarter
+126 424 000 USD
Last Quarter
+122 710 000 USD
Current Year
+313 672 000 USD
Last Year
+179 810 000 USD
Current Quarter
+107 147 000 USD
Last Quarter
+97 961 000 USD
Key Figures CN2
1 year
3 years
5 years
10 years
EBITDA
211 432 000 USD
Operating Margin TTM
PE Ratio
20.2797
Return On Assets TTM
18.35 %
PEG Ratio
–
Return On Equity TTM
28.29 %
Wall Street Target Price
31 USD
Revenue TTM
460 481 984 USD
Book Value
5.54 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
25.3 %
Dividend Yield
–
Gross Profit TTM
160 021 000 USD
Earnings per share
1.18 USD
Diluted Eps TTM
1.18 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
31.01 %
Dividend Analytics CN2
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CN2
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation CN2
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
20.2797
Forward PE
11.4286
Enterprise Value Revenue
5.0687
Price Sales TTM
6.1983
Enterprise Value EBITDA
11.0393
Price Book MRQ
4.1957
Financials CN2
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CN2
For 52 weeks
12.9 USD
24.27 USD
50 Day MA
20.74 USD
Shares Short Prior Month
5 751 460
200 Day MA
17.22 USD
Short Ratio
6.11
Shares Short
5 960 967
Short Percent
6.24 %
BeatStart